Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 3
2005 4
2006 1
2007 1
2008 4
2009 4
2010 3
2011 3
2012 2
2013 5
2016 1
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Neuropsychiatric side effects of interferon-alfa therapy.
Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Van Gool AR, et al. Pharm World Sci. 2003 Feb;25(1):11-20. doi: 10.1023/a:1022449613907. Pharm World Sci. 2003. PMID: 12661471 Review.
IL-12: a promising adjuvant for cancer vaccination.
Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. Portielje JE, et al. Cancer Immunol Immunother. 2003 Mar;52(3):133-44. doi: 10.1007/s00262-002-0356-5. Epub 2003 Feb 12. Cancer Immunol Immunother. 2003. PMID: 12649742 Free PMC article. Review.
Side effects of interferon-alpha therapy.
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Sleijfer S, et al. Pharm World Sci. 2005 Dec;27(6):423-31. doi: 10.1007/s11096-005-1319-7. Pharm World Sci. 2005. PMID: 16341948
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG. Ulloa-Montoya F, et al. J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715562 Clinical Trial.
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM. Schouwenburg MG, et al. Among authors: kruit wh. Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453. Melanoma Res. 2018. PMID: 29750749
[Revision of the national guideline 'Melanoma'].
Veerbeek L, Kruit WH, de Wilt J, Mooi WJ, Bergman W; Multidisciplinaire Richtlijnwerkgroep Melanoom. Veerbeek L, et al. Ned Tijdschr Geneeskd. 2013;157(12):A6136. Ned Tijdschr Geneeskd. 2013. PMID: 23515047 Dutch.
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ. Jochems A, et al. Among authors: kruit wh. Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25. Eur J Cancer. 2017. PMID: 28030784
33 results